MTHFR Gene and Your Methylation Cycle | Decoding Inflammation

By Decoding Inflammation · 2026-07-02 · 8 min

One gene encodes an enzyme that sits at the center of the folate cycle, the biochemical pathway your cells use to process and distribute one-carbon units across dozens of metabolic processes. That gene is MTHFR, which stands for methylenetetrahydrofolate reductase, the enzyme it encodes. The enzyme converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate. That conversion is a critical step in a cascade your cells depend on to methylate homocysteine, an amino acid, back into methionine, another amino acid that the body requires for protein synthesis, epigenetic regulation, and neurotransmitter production.

A peer-reviewed clinical overview published in PMC in July 2024 confirmed that MTHFR genetic testing investigates two specific variants: 677C>T and 1298A>C. These two variants are among the most frequently ordered in clinical genetic testing, with documented associations across multiple disease categories including cardiovascular disease, cancer, autism spectrum disorder, psychiatric conditions, and congenital malformations.

WHAT THE VARIANTS DO AT THE ENZYME LEVEL

The MTHFR gene sits on chromosome 1 at position 1p36.22. Two variants in this gene carry confirmed effects on how efficiently the enzyme functions.

The 677C>T variant, identified by its reference number rs1801133, produces a single amino acid substitution in the enzyme's catalytic domain. Alanine at position 222 changes to valine. This substitution increases the enzyme's thermolability, meaning the enzyme becomes less stable at normal body temperature, and reduces its affinity for FAD, the cofactor it requires to function. A 2025 review published in Genes (Basel) by Araszkiewicz and colleagues at Poznan University of Medical Sciences confirmed that this variant reduces enzyme efficiency by approximately 35 percent per mutated allele. A person who inherits the variant from both parents carries two copies of the substitution. That person's MTHFR enzyme operates at substantially reduced capacity.

The 1298A>C variant, identified by reference number rs1801131, produces a different amino acid substitution. Glutamate at position 429 changes to alanine. Carrying one copy of this variant alone produces a smaller measurable reduction in enzyme activity. Carrying both the 677C>T variant and the 1298A>C variant together, a configuration called compound heterozygosity, produces a greater combined reduction in enzyme function than either variant causes independently.

The 677C>T variant appears in 30 to 40 percent of the global population on average, with geographic variation ranging from near zero to over 40 percent depending on ancestry. The variant does not cause severe MTHFR deficiency. It reduces enzyme efficiency within a range that the body can sometimes compensate for through adequate dietary folate intake, and sometimes cannot.

THE FOLATE CYCLE AND THE METHYLATION CONSEQUENCE

When MTHFR activity decreases, less 5-methyltetrahydrofolate reaches the enzyme methionine synthase. Methionine synthase requires 5-methyltetrahydrofolate to convert homocysteine to methionine. When this conversion slows, homocysteine accumulates in the bloodstream. This accumulation carries its own name in clinical literature: hyperhomocysteinemia, or elevated homocysteine levels.

Homocysteine at elevated concentrations damages the inner lining of blood vessels, promotes oxidative stress by generating reactive oxygen species (ROS), molecules that damage cell membranes, proteins, and DNA when they accumulate faster than the cell's antioxidant systems neutralize them, and disrupts the availability of methyl groups that the genome requires for DNA methylation. DNA methylation, the attachment of methyl groups to specific positions on the DNA strand, governs which genes the cell reads and at what level. A disruption in methyl group availability propagates downstream across every system that depends on methylation for normal gene regulation.

THE DISEASE ASSOCIATION LANDSCAPE

The 2025 Poznan review by Araszkiewicz and colleagues synthesized evidence from meta-analyses and reviews published between 2015 and 2025. The review confirmed documented associations between MTHFR polymorphisms and cardiovascular diseases, oxidative stress pathology, neurological and psychiatric disorders including autism spectrum disorder, Alzheimer's disease, schizophrenia, and major depressive disorder, fertility and pregnancy complications including recurrent pregnancy loss and neural tube defects, metabolic disorders including diabetes mellitus and inflammatory bowel disease, and oncological conditions including breast, prostate, and ovarian cancers, leukemia, and autoimmune diseases including rheumatoid arthritis.

The review also noted that the strength of these associations varies across disease categories. Some associations carry robust evidence from multiple large meta-analyses. Others require further investigation. Environmental factors, including ethnic background and dietary folate intake, influence the degree to which the variant translates into elevated disease risk.

WHAT THIS MEANS AT THE INDIVIDUAL LEVEL

The MTHFR enzyme does not operate in isolation. It sits inside a network of interdependent reactions that include the folate cycle, the methionine cycle, and the transsulfuration pathway, the series of reactions that converts homocysteine into cysteine and then into glutathione, the cell's primary antioxidant. A reduction in MTHFR efficiency does not simply slow one reaction. It applies pressure across every downstream pathway that depends on the methyl groups the folate cycle supplies.

Folate availability modifies the functional consequence of the 677C>T variant. A person who carries reduced-function variants and consumes adequate folate through diet or supplementation may maintain sufficient 5-methyltetrahydrofolate production to keep homocysteine within a normal range. A person who carries the same variants with insufficient folate intake faces a more significant metabolic bottleneck.

The MTHFR variants are among the best-documented examples of how a single gene position, a single nucleotide change in the three-billion-letter genome, can alter the efficiency of a central metabolic enzyme in ways that cascade outward across inflammation, cardiovascular function, neurological health, and DNA repair capacity.

Disclaimer: The content on this platform is strictly educational and informational. Nothing here constitutes a medical diagnosis, clinical assessment, or treatment recommendation. All clinical decisions are handled separately through qualified medical providers.